IO Biotech, Inc. (IOBT) |
|
2.82 0.03 (1.08%)
|
01-27 16:00 |
|
Open: |
2.74 |
Pre. Close: |
2.79 |
|
High:
|
2.87 |
Low:
|
2.74 |
|
Volume:
|
21,892 |
Market Cap:
|
81(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:32 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.76 One year: 4.39 |
| Support: |
Support1: 2.57 Support2: 2.17 |
| Resistance: |
Resistance1: 3.22 Resistance2: 3.76 |
| Pivot: |
2.64  |
| Moving Average: |
MA(5): 2.84  MA(20): 2.6
MA(100): 2.69 MA(250): 4.37 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 52.4 %D(3): 57.8 |
| RSI: |
RSI(14): 55.7 |
| 52-week: |
High: 9.77 Low: 2.15 |
| Average Vol(K): |
3-Month: 84 (K) 10-Days: 171 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IOBT ] has closed below upper band by 27.8%. Bollinger Bands are 14.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.87 - 2.88 |
2.88 - 2.9 |
|
Low:
|
2.71 - 2.72 |
2.72 - 2.74 |
|
Close:
|
2.8 - 2.82 |
2.82 - 2.84 |
|
Company Description |
|
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. |
Headline News |
Mon, 23 Jan 2023
2023-01-23 | NDAQ:IOBT | Press Release | IO Biotech Inc. - Stockhouse
Fri, 20 Jan 2023
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully - Simply Wall St
Thu, 19 Jan 2023
Internet of Battlefield Things (IoBT) Market 2023 In-depth Analysis by ... - Digital Journal
Mon, 09 Jan 2023
IO Biotech (IOBT) Provides Business Update - StreetInsider.com
Mon, 28 Nov 2022
Healthcare Stocks Moving Monday: AXSM, NUTX, KTRA, IOBT, CINC, TCBP, PKBO, ONCS - InvestorsObserver
Wed, 16 Nov 2022
Abdelzaher's IoBT REIGN Alliance Receives 5-year Extension Worth ... - Illinois Computer Science News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
29 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
11.1 (%) |
|
% Held by Institutions
|
82.6 (%) |
|
Shares Short
|
11 (K) |
|
Shares Short P.Month
|
32 (K) |
Stock Financials |
|
EPS
|
-7.54 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.32 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-40.6 |
|
Return on Equity (ttm)
|
-72.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-66 (M) |
|
Levered Free Cash Flow
|
-37 (M) |
Stock Valuations |
|
PE Ratio
|
-0.38 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.52 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.23 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
